

# PRIOR AUTHORIZATION CRITERIA

**BRAND NAME**  
(generic)

**REGRANEX (all topical)**  
(becaplermin)

**Status: CVS Caremark® Criteria**

**Type: Initial Prior Authorization with Quantity Limit**

## POLICY

### FDA-APPROVED INDICATIONS

Regranex is indicated for the treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply, when used as an adjunct to, and not a substitute for, good ulcer care practices including initial sharp debridement, pressure relief and infection control.

### Limitations of Use:

The efficacy of Regranex has not been established for the treatment of pressure ulcers and venous stasis ulcers and has not been evaluated for the treatment of diabetic neuropathic ulcers that do not extend through the dermis into subcutaneous tissue [Stage I or II, International Association of Enterostomal Therapy (IAET) staging classification] or ischemic diabetic ulcers.

The effects of becaplermin on exposed joints, tendons, ligaments, and bone have not been established in humans.

Regranex is not intended to be used in wounds that close by primary intention.

## COVERAGE CRITERIA

### **Lower Extremity Diabetic Neuropathic Ulcers**

Authorization may be granted when the requested drug is being prescribed for the treatment of lower extremity diabetic neuropathic ulcers that extends into the subcutaneous tissue or beyond and has an adequate blood supply when ALL of the following criteria are met:

- Good ulcer care practices including initial sharp debridement, pressure relief, and infection control will be performed
- If additional quantities are being requested, then the requested drug is being prescribed to treat an ulcer greater than 2.5 square inches in size OR multiple ulcers

### QUANTITY LIMITS APPLY

30 grams per 25 days\*

For multiple ulcers or an ulcer greater than 2.5 square inches in size: 60 grams per 25 days\*

\* The duration of 25 days is used for a 30-day fill period to allow time for refill processing.

\*\* ***This drug is for short-term acute use; therefore, the intent is for prescriptions of the requested drug to be filled one month at a time; there should be no 3-month supplies filled.***

### DURATION OF APPROVAL (DOA)

- 186-C: DOA: 20 weeks

## REFERENCES

Regranex PA with Limit Policy 186-C UDR 03-2024

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

©2024 CVS Health and/or its affiliates. All rights reserved. 106-58428A 021423

1. Regranex [package insert]. Fort Worth, TX: Smith & Nephew Inc.; August 2019.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024. <https://online.lexi.com>. Accessed January 17, 2024.
3. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 01/17/2024).

Regranex PA with Limit Policy 186-C UDR 03-2024

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

©2024 CVS Health and/or its affiliates. All rights reserved. 106-58428A 021423